Feature Review Papers in Section “Pharmaceutical Processes”

A special issue of Processes (ISSN 2227-9717). This special issue belongs to the section "Pharmaceutical Processes".

Deadline for manuscript submissions: 15 February 2025 | Viewed by 928

Special Issue Editor


E-Mail Website
Guest Editor
Foamlab, Dipartimento di Ingegneria Chimica, dei Materiali e della Produzione Industriale, University of Naples Federico II, P.le V. Tecchio, 80, 80125 Napoli, Italy
Interests: drug delivery systems; foams; material science; pharmaceutical material science
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are excited to announce the launch of a Special Issue dedicated to “Feature Review Papers in Section “Pharmaceutical Processes””. This special edition aims to bring together the latest insights and comprehensive reviews from leading experts in the field, focusing on innovative techniques, advancements, and challenges within pharmaceutical processes. Covering a wide spectrum of topics, from drug formulation and delivery to quality control and regulatory compliance, this collection of feature review papers will serve as an invaluable resource for researchers, practitioners, and policymakers. Submit your review paper to this Special Issue and be part of the efforts to shape the future of pharmaceutical science and engineering. By curating this collection, we aim to improve knowledge sharing about innovative solutions in this field. We invite you to contribute your expertise and perspectives, thereby advancing the understanding and application of pharmaceutical processes. The participation of all experts in topics related to drug release is welcome, driving the quest for safer, more effective, and more efficient pharmaceutical solutions.

Dr. Paolo Trucillo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Processes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery systems
  • plants for drug delivery
  • materials for drug delivery
  • liposomes
  • niosomes
  • biocompatible polymers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 3066 KiB  
Review
Role of Natural Phytoconstituents as a Potential Bioenhancer of Anti-Cancer and Anti-Microbial Agents: Spotlight on the Mechanism of Action, Clinical Studies and Patents
by Dhanalekshmi Unnikrishnan Meenakshi, Gurpreet Kaur Narde, Alka Ahuja, Md Jawaid Akhtar and Shah Alam Khan
Processes 2024, 12(10), 2060; https://doi.org/10.3390/pr12102060 - 24 Sep 2024
Viewed by 609
Abstract
A drug design strategy with reduced side effects and economic feasibility is desirable for fatal diseases. Increasing the bioavailability of a drug using a bioenhancer is a smart strategy. Herbal/natural bioenhancers with no probable side effects are an ideal choice to enhance the [...] Read more.
A drug design strategy with reduced side effects and economic feasibility is desirable for fatal diseases. Increasing the bioavailability of a drug using a bioenhancer is a smart strategy. Herbal/natural bioenhancers with no probable side effects are an ideal choice to enhance the pharmacokinetics of a therapeutic drug synergistically. The mechanism of bioenhancers relies on the retention of the drug molecule in the cell without causing any changes in the metabolic activity. Most of the herbal bioenhancers achieve this feat by inhibiting metabolic enzymes such as cytochrome P450 and Uridine 5′-diphospho-glucuronosyltransferase. The efflux pump p-glycoprotein, responsible for removal of xenobiotics, is also inhibited by herbal/natural bioenhancers. The increased bioavailability because of the higher Cmax and tmax of chemotherapeutics or anti-infectious agents such as rifampicin can result in a lower drug dosage regimen. The reduction in drug dosage is directly linked to fewer side effects and economic viability. Further, there is a significant effort in clinical trials to incorporate bioenhancers in drug regimens for cancer. The role of herbal/natural bioenhancers and their potential to augment the bioavailability of therapeutics used in cancer and infectious diseases, with a focus on the mechanisms of action, clinical studies and patents, have been summarized in this review article. Full article
(This article belongs to the Special Issue Feature Review Papers in Section “Pharmaceutical Processes”)
Show Figures

Graphical abstract

Back to TopTop